Logo Image
|Webcasts|June 11, 2021

Improving Sensitivity of LC-MS Methods for Characterization and Quantitation of Synthetic Oligonucleotides

Author(s)Phenomenex

Friday, June 11, 2021 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

Register Free: ​ https://www.chromatographyonline.com/lcgc_w/improving

Event Overview:

The primary method for quantitation and characterization of synthetic oligonucleotides is liquid chromatography–mass spectrometry (LC–MS). Whether for characterizing process- and product-related impurities or bioanalytical pharmacokinetic studies, improving method sensitivity is of critical importance.

In this presentation, we discuss how LC–MS sensitivity can be improved with mobile phase optimization and column selection. We also demonstrate how one can minimize adduct formation and improve ionization efficiency, which can improve MS sensitivity for improved characterization and quantitation data.

Key Learning Objectives:

  • Learn the fundamentals of electrospray ionization of oligonucleotides, and how different method parameters can affect performance
  • Understand the role of mobile phase and column chemistry in LC–MS methods for oligonucleotides
  • Determine experimental parameters to ensure high sensitivity, robust LC–MS methods for synthetic oligonucleotides

Speakers:

Brian Rivera
Senior Product Manager- Biologics
Phenomenex

Times and Dates:

Friday, June 11, 2021 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

Sponsor:

Phenomenex

Register free: https://www.chromatographyonline.com/lcgc_w/improving

Related to this article

View more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more